Top Markets
Coin of the day
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

AMPH
주식 순위 #9658
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho... Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
주가
$22.00
마지막 동기화: 2026-08-28
시가총액
$970.00M
변동 (1일)
0.54%
변동 (1년)
-28.16%
국가
US
거래 Amphastar Pharmaceuticals, Inc. (AMPH)

카테고리

B의 시가 총액을 가진 AMPH의 가격
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
AMPH
$22.00
의 시가총액 Amphastar Pharmaceuticals, Inc.(AMPH)
시가총액: $970.00M
August 2026 기준으로 Amphastar Pharmaceuticals, Inc.의 시가총액은 $970.00M입니다. 이는 당사 데이터에 따르면 Amphastar Pharmaceuticals, Inc.이 세계에서 9658th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2014부터 2026까지 Amphastar Pharmaceuticals, Inc.의 시가총액 기록
AMPH 가장 인기있는 상위 5 가지 stocks과 비교하여
AMPH의 가격 자산 b b의 시장 결과
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$119,381 $970.00M
$5.264T +542,569.16%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$106,622 $970.00M
$4.701T +484,569.75%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$94,735.79 $970.00M
$4.177T +430,538.77%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$86,576.28 $970.00M
$3.817T +393,448.23%
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc.
$65,006.74 $970.00M
$2.866T +295,399.94%